Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents

• Published in: American journal of physiology: endocrinology and metabolism Vol. 311; no. 2; pp. E461 - E470
• Main Authors: Perry, Rachel J., Cardone, Rebecca L., Petersen, Max C., Zhang, Dongyan, Fouqueray, Pascale, Hallakou-Bozec, Sophie, Bolze, Sébastien, Shulman, Gerald I., Petersen, Kitt Falk, Kibbey, Richard G.
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.08.2016
• Series: Islet Biology
• Subjects: Animals; Blood Glucose - drug effects; Blood Glucose - metabolism; Call for Papers; Diet, High-Fat; Fasting; Glucose - metabolism; Glucose Clamp Technique; Hypoglycemic Agents - pharmacology; Insulin - metabolism; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - metabolism; Liver - drug effects; Liver - metabolism; Male; Mice; Mice, Inbred C57BL; Postprandial Period; Rats; Rats, Sprague-Dawley; Triazines - pharmacology; β-cell; imeglimin; glucose-stimulated insulin secretion

Imeglimin is a promising new oral antihyperglycemic agent that has been studied in clinical trials as a possible monotherapy or add-on therapy to lower fasting plasma glucose and improve hemoglobin A 1c (1–3, 9). Imeglimin was shown to improve both fasting and postprandial glycemia and to increase i...